Rights and permissions
About this article
Cite this article
First-line FOLFIRINOX “attractive cost-effective treatment“ for mPC. Pharmacoecon. Outcomes News 646, 6 (2012). https://doi.org/10.1007/BF03272336
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03272336